Literature DB >> 10482923

PKCbetaI mediates the inhibition of P2Y receptor-induced inositol phosphate formation in endothelial cells.

B C Chen1, W W Lin.   

Abstract

1. Bovine pulmonary artery endothelium (CPAE) expresses phospholipase C (PLC)-linked P2Y1 and P2Y2 receptors, for them 2-methylthio-ATP (2MeSATP) and UTP are respective agonists. Here, we have investigated the particular protein kinase C (PKC) isoform(s) responsible for the inhibition of P2Y1 and P2Y2 receptor-evoked inositol phosphate (IP) formation by phorbol 12-myristate 13-acetate (PMA). 2. Although short-term (20 min) pretreatment of cells with PMA attenuated 2MeSATP- and UTP-induced phosphoinositide (PI) breakdown, this inhibition was lost after 15 h. Preincubation with PMA for 24 h, on the contrary, potentiated 2MeSATP and UTP responses. The IP formation stimulated by NaF was unaltered by PMA pretreatment. 3. Western blot analysis showed that treatment of CPAE with PMA resulted in a rapid translocation of PKC isoform betaI, epsilon and mu, but not lambda, from the cytosol to the membrane fraction. 4. Pretreatment of the selective PKC inhibitor Ro 31-8220 attenuated the inhibitory effect of PMA on IP formation. Go 6976 (an inhibitor of conventional PKCalpha, beta and gamma) and LY 379196 (a selective PKCbeta inhibitor) also dose-dependently inhibited the PMA-mediated desensitization. 5. Transfection of PKCbeta-specific antisense oligonucleotide reduced PKCbetaI protein level and inhibited PMA-mediated PI reduction. 6. RT - PCR analysis showed that PMA treatment for 4 - 24 h up-regulated P2Y1 and P2Y2 receptors at the mRNA levels. 7. These results suggest that PKCbetaI may exert a negative feedback regulation on endothelial P2Y1 and P2Y2 receptor-mediated PI turnover. The down-regulation of PKCbetaI and enhanced P2Y receptor expression together might contribute to the late PI enhancing effect of PMA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482923      PMCID: PMC1566172          DOI: 10.1038/sj.bjp.0702727

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

Review 1.  Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C.

Authors:  Y Nishizuka
Journal:  Science       Date:  1992-10-23       Impact factor: 47.728

2.  Possible role of protein phosphorylation in the mitogenic effect of high density lipoproteins on cultured vascular endothelial cells.

Authors:  J M Darbon; J F Tournier; J P Tauber; F Bayard
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

Review 3.  The role of protein kinase C in cell surface signal transduction and tumour promotion.

Authors:  Y Nishizuka
Journal:  Nature       Date:  1984 Apr 19-25       Impact factor: 49.962

4.  Protein kinase C epsilon-dependent pathway of extracellular signal-regulated protein kinase activation by P2Y1 and P2Y2 purinoceptors that activate cytosolic phospholipase A2 in endothelial cells.

Authors:  B C Chen; L L Lin; W W Lin
Journal:  Eur J Pharmacol       Date:  1999-05-28       Impact factor: 4.432

5.  Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976.

Authors:  G Martiny-Baron; M G Kazanietz; H Mischak; P M Blumberg; G Kochs; H Hug; D Marmé; C Schächtele
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

6.  Regulation of bradykinin-induced phosphoinositide turnover in cultured cerebellar astrocytes: possible role of protein kinase C.

Authors:  W W Lin; D M Chuang
Journal:  Neurochem Int       Date:  1992-12       Impact factor: 3.921

7.  ATP receptor-mediated synaptic currents in the central nervous system.

Authors:  F A Edwards; A J Gibb; D Colquhoun
Journal:  Nature       Date:  1992-09-10       Impact factor: 49.962

8.  Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man.

Authors:  G V Born; M A Kratzer
Journal:  J Physiol       Date:  1984-09       Impact factor: 5.182

9.  Differential regulation of inositol 1,4,5-trisphosphate by co-existing P2Y-purinoceptors and nucleotide receptors on bovine aortic endothelial cells.

Authors:  J R Purkiss; G F Wilkinson; M R Boarder
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

10.  Coexpression of P2Y and P2U receptors on aortic endothelial cells. Comparison of cell localization and signaling pathways.

Authors:  D Communi; E Raspe; S Pirotton; J M Boeynaems
Journal:  Circ Res       Date:  1995-02       Impact factor: 17.367

View more
  6 in total

1.  ADP-sensitive purinoceptors induce steroidogenesis via adenylyl cyclase activation in bovine adrenocortical fasciculata cells.

Authors:  Haruhisa Nishi; Fusao Kato; Eiji Masaki; Masahiro Kawamura
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

2.  Two subtypes of G protein-coupled nucleotide receptors, P2Y(1) and P2Y(2) are involved in calcium signalling in glioma C6 cells.

Authors:  P Sabala; R Czajkowski; K Przybyłek; K Kalita; L Kaczmarek; J Barańska
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  Phe27Cys polymorphism of the human delta opioid receptor predisposes cells to compromised calcium signaling.

Authors:  Jussi T Tuusa; Ulla E Petäjä-Repo
Journal:  Mol Cell Biochem       Date:  2011-01-14       Impact factor: 3.396

4.  Differential regulation of P2Y(11) receptor-mediated signalling to phospholipase C and adenylyl cyclase by protein kinase C in HL-60 promyelocytes.

Authors:  B C Suh; T D Kim; I S Lee; K T Kim
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

5.  Desensitization of endothelial P2Y1 receptors by PKC-dependent mechanisms in pressurized rat small mesenteric arteries.

Authors:  R Rodríguez-Rodríguez; P Yarova; P Winter; K A Dora
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

6.  Integration of P2Y receptor-activated signal transduction pathways in G protein-dependent signalling networks.

Authors:  Kristof Van Kolen; Herman Slegers
Journal:  Purinergic Signal       Date:  2006-06-07       Impact factor: 3.765

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.